|
gptkbp:instanceOf
|
biotechnology tool
genome editing technology
molecular biology technique
|
|
gptkbp:alternativeTo
|
gptkb:TALEN
gptkb:ZFN
|
|
gptkbp:application
|
gptkb:medicine
agriculture
biomedical research
gene therapy
disease modeling
functional genomics
|
|
gptkbp:component
|
gptkb:Cas9_protein
gptkb:guide_RNA
|
|
gptkbp:deliveredBy
|
lipid nanoparticles
viral vectors
electroporation
microinjection
|
|
gptkbp:developedBy
|
gptkb:Emmanuelle_Charpentier
gptkb:Jennifer_Doudna
|
|
gptkbp:discoveredIn
|
2012
|
|
gptkbp:firstHumanTrial
|
2016
|
|
gptkbp:firstHumanTrialLocation
|
gptkb:China
|
|
gptkbp:firstUSHumanTrial
|
2019
|
|
gptkbp:firstUSHumanTrialLocation
|
gptkb:University_of_Pennsylvania
|
|
gptkbp:hasEthics
|
germline editing
off-target effects
designer babies
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CRISPR-Cas9
|
|
gptkbp:mechanismOfAction
|
induces double-strand breaks in DNA
uses RNA-guided DNA endonuclease activity
|
|
gptkbp:NobelPrizeYear
|
gptkb:2020_Nobel_Prize_in_Chemistry
gptkb:Emmanuelle_Charpentier
gptkb:Jennifer_Doudna
|
|
gptkbp:notablePublication
|
gptkb:Nature
gptkb:science
2012
|
|
gptkbp:origin
|
gptkb:Streptococcus_pyogenes
bacterial immune system
|
|
gptkbp:patentDispute
|
gptkb:Broad_Institute
gptkb:University_of_California
|
|
gptkbp:regulates
|
gptkb:FDA
gptkb:NIH
gptkb:EMA
|
|
gptkbp:relatedTo
|
gptkb:CRISPR
gptkb:Cas12
gptkb:Cas13
|
|
gptkbp:target
|
gptkb:gene
|
|
gptkbp:usedFor
|
gene editing
genome engineering
gene activation
gene knockout
gene repression
|
|
gptkbp:bfsParent
|
gptkb:Pairwise_Plants
gptkb:CRISPR
|
|
gptkbp:bfsLayer
|
5
|